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and intrapleural ﬁbrinolysis by streptokinase in complicated parapneumonic effusion and empyema
regarding both efﬁcacy and safety.
Patients and methods: This study included 40 inpatients with complicated parapneumonic effu-
sion and empyema. Included patients had frank pus, pH< 7.20, positive Gram stain or culture.
Patients were randomly divided into two groups; ﬁrst group was managed by medical thoracoscopy
(20 patients) and the second group was managed by intercostal tube drainage plus intrapleural
instillation of streptokinase (20 patients). Patients who were diagnosed as tuberculosis, bronchial
carcinoma, chronic obstructive airway diseases and uncompensated liver cell failure were excluded
from the study. Clinical, laboratory, radiological data and hospital stay duration were adopted for
comparison between two groups.
Results: Comparing both groups, in group 1, 19 patients (95%) had total improvement and 1
patient (5%) had partial improvement, in group 2, 12 patients (60%) had total improvement and
6 patients (40%) had partial improvement in radiological end points which is statistically signiﬁ-
cant. The duration of hospital stay was 4.70 ± 1.45 days in group 1 and 6.95 ± 2.04 days in group
890 A. Hewidy, M. Elshafey2 which is statistically signiﬁcant. There were no serious complications, and no mortality in both
groups.
Conclusion: Medical thoracoscopy is superior to streptokinase ﬁbrinolysis in complicated para-
pneumonic effusions and empyema in terms of safety and efﬁcacy.
ª 2014 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier
B V Open access under CC BY-NC-ND license.. .Introduction
Parapneumonic effusion is a pleural effusion associated with
bacterial pneumonia, lung abscess or bronchiectasis. An effu-
sion is called empyema when the concentration of leukocytes
becomes macroscopically evident as a thick, highly viscous,
whitish-yellow, opaque, and turbid ﬂuid (pus) [1].
Parapneumonic effusion can be divided into three stages:
the exudative phase in which, ﬂuid moves into the pleural
space due to locally increased capillary vascular permeability
and the activation of immune processes such as neutrophil
migration. Pro-inﬂammatory cytokines including interleukin
(IL)-6, IL-8 and tumor necrosis factor alpha (TNF-a) produce
changes in the anatomical shape of pleural mesothelial cells
creating intercellular ‘gaps’ which further enhance permeabil-
ity and additional ﬂuid accumulates. The accumulating pleural
ﬂuid has a normal glucose level (>40 mg/dL) and pH (>7.20),
with no detectable bacteria, and hence no microbiological or
biochemical evidence of bacterial invasion. The effusion will
usually resolve spontaneously with antibiotic therapy for the
underlying pneumonia [2].
In the ﬁbropurulent phase, the high levels of ﬁbrinolytic
activity which characterize the normal pleural space are rap-
idly depressed and titers of speciﬁc inhibitors of ﬁbrinolytic
activity such as tissue plasminogen activator inhibitors (PAI)
1 and 2 rise. PAI 1 and 2 and mediators such as TNF-a are
directly released from mesothelial cells and are increased in
infected pleural ﬂuid compared with ﬂuid from malignancy
and other causes. This leads to ﬁbrin deposition over the vis-
ceral and parietal pleura, with the division of the pleural space
by ﬁbrinous septae, producing ﬂuid loculation and pleural
adhesions [3].
In the organizing stage there is proliferation of ﬁbroblasts
and evolution of pleural scarring which forms an inelastic peel
on both pleural surfaces with dense ﬁbrous septations across
the pleural cavity. As this solid ﬁbrous peel replaces the soft
ﬁbrin, lung re-expansion is prevented, impairing lung function
[4].
PPE is categorized to 4 categories for evaluating the risk of
poor outcome in patients with PPE based on three variables,
pleural space anatomy, pleural ﬂuid bacteriology, and pleural
ﬂuid chemistry. Pleural effusion drainage for patients with
moderate (category 3) or high (category 4) risk for a poor out-
come, but not for patients with very low (category 1) or low
(category 2) risk for a poor outcome.
 Category 1 (parapneumonic effusion)
o Minimal free-ﬂowing ﬂuid, smaller than 10 mm on
decubitus ﬁlms.
o Culture, Gram stain, and pH unknown.
o No thoracentesis needed; treatment with antibiotics
alone. Category 2 (uncomplicated parapneumonic effusion)
o Larger than 10 mm ﬂuid and less than half the hemitho-
rax on decubitus ﬁlms.
o Gram stain and culture negative.
o pH higher than 7.20.
o Treatment with antibiotics alone.
 Category 3 (complicated parapneumonic effusion)
o Large free-ﬂowing effusion, more than half the
hemithorax.
o pH lower than 7.20, LDH level greater than 1000 U/L
and glucose level greater than 40 mg/dL.
o Gram stain or culture positive.
o Treatment with tube thoracostomy and antibiotics.
o Multiloculated effusions may require multiple tubes.
o Thrombolytics may help resolution.
 Category 4 (empyema)
o Large free-ﬂowing effusion, greater than or equal to half
the hemithorax.
o Loculated effusion or effusion with thickened pleura.
o Gross pus on aspiration.
o Treatment with tube thoracostomy.
o Thrombolytics may help resolution.
o May require decortications [5].
Indications for pleural ﬂuid drainage in pleural infection:
1- Patients with frankly purulent or turbid/cloudy pleural
ﬂuid on sampling should receive prompt pleural space
chest tube drainage.
2- The presence of organisms identiﬁed by Gram stain and/
or culture from a non-purulent pleural ﬂuid sample indi-
cate/indicates that pleural infection is established and
should lead to prompt chest tube drainage.
3- Pleural ﬂuid pH < 7.2 in patients with suspected pleural
infection indicates a need for chest tube drainage.
4- Parapneumonic effusions that do not fulﬁll any of these
criteria for chest tube drainage could be treated with
antibiotics alone provided clinical progress is good.
5- Poor clinical progress during treatment with antibiotics
alone should lead to prompt patient review, repeat pleu-
ral ﬂuid sampling and probably chest tube drainage [6].
Patients and methods
This study included 40 patients with complicated parapneu-
monic effusion and empyema were admitted to chest depart-
ment Mansoura university hospital from January 2012
to July 2013, informed consent was obtained from all
patients. Patients had both symptoms and signs of a bacterial
Table 2 Clinical data of both groups.
Group 1 Group 2 v2 P
MT (n= 20) ICT-SK (n= 20)
No % No %
Dyspnea 20 100 20 100 – –
Productive cough 15 75 16 80 0.956 0.473*
Chest pain 17 85 18 90 0.229 0.633
Hemoptysis 1 5 1 5 0.000 1.0
Fever 20 100 20 100 1.290 0.256
Table 1 Demographic data and smoking status of both
groups.
Group 1 Group 2 v2 P
MT (n= 20) ICT (n= 20)
No % No %
Age 45.60 ± 8.91 48.60 ± 12.43 t= 0.877 0.386
Sex
Male 11 55 13 65 0.417 0.519
Female 9 45 7 35
Smoking
Smoker 13 65 9 45 1.627 0.443
Non-smoker 4 20 6 30
Ex-smoker 3 15 5 25
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chest pain and dyspnea. Full laboratory work up was done,
plain chest X-ray, trans-thoracic ultrasound chest to detect loc-
ulations and CT chest were done before and after intervention.
Pleural ﬂuid aspiration was done and sent for biochemical
analysis including, pH, LDH, protein content and cellular pat-
tern also Gram stain and culture were done for aerobic and
anaerobic organisms prior to initiation of antibiotic therapy.
Included patients had frank pus, pH < 7.20, positive Gram
stain or culture. Patients were randomly divided into two
groups; ﬁrst group was managed by medical thoracoscopy
(MT) and the second group was managed by intercostal tube
drainage (ICT) plus intrapleural instillation of streptokinase
as ﬁbrinolytic agent. Patients who were diagnosed with tuber-
culosis, bronchial carcinoma, chronic obstructive airway dis-
eases and diabetic patients were excluded from the study.
Medical thoracoscopy was performed in the ﬁrst group
under local anesthesia and conscious sedation (midazolam
5 mg) in an endoscopy room. Patients were placed in lateral
decubitus with the affected side up. The trocar point of entry
was chosen by ultrasonography to identify the point where
the pus collection is largest and the position of the diaphragm,
which is often elevated. 11-mm rigid rod lens telescope
(STORZ) was introduced in the pleural cavity, suction of all
ﬂuids was done, cutting and removal of adhesions and thick-
ened pleura and opening of multiple loculations were done
by using forceps through forceps channel, lastly the pleural
cavity was irrigated by normal saline and intercostal tube
(30 F) was inserted in the pleural cavity.
To patients undergoing intercostal tube drainage (30 F)
insertion in the pleural cavity, after 2 h of drainage, streptoki-
nase 250,000 U in 100 ml of normal saline solution was instil-
lated through intercostal tube to the pleural cavity, tube was
clamped for 4 h then unclamped to continue drainage, this
procedure was repeated daily for maximum of 5 days. Inter-
costal tube in both groups was left until ﬂuid drainage becomes
less than 100 ml/day. Clinical, laboratory, radiological and
hospital stay duration end points were adopted for comparing
the two interventions as absence of frank pus in the drainage,
fever, leukocytic count, and chest X-ray and CT opacity. Inad-
equate drainage, was deﬁned on radiological basis as the pres-
ence of >50% of the original amount of pleural ﬂuid on a
chest X-ray [7]. Patients of both groups received antibiotic
therapy covering most likely possible organisms; third genera-
tion cephalosporins, respiratory quinolone and metronidazole,
later readjusted according to the results of bacterial culture.
Statistical methods
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 15. Qualitative data were presented as number
and percent. Comparison between groups was done by Chi-
Square test. Quantitative data were presented as mean ± SD.
Student’s t-test was used to compare between two groups.
P< 0.05 was considered to be statistically signiﬁcant.
Results
This study included 40 patients (24 males and 16 females) with
complicated parapneumonic effusion (23 patients) and empy-
ema (17 patients). The patients were randomly divided intotwo groups, medical thoracoscopy (MT) group and group 2
intercostal tube with streptokinase group and both groups
were compared with regard to clinical, laboratory, radiological
and hospital stay duration endpoints.
The mean age for group 1 was 45.6 ± 8.9 and the mean age
for group 2 was 48.6 ± 12.4. Group 1 included 11 males (55%)
and 9 females (45%) while group 2 included 13 males (65%)
and 7 females (35%). In group 1, 13 patients (65%) were
smokers, 4 patients (20%) were non-smokers and 3 patients
(15%) were ex-smokers. In group 2, 9 patients (45%) were
smokers, 6 patients (30%) were non-smokers and 5 patients
(25%) were ex-smokers (see Table 1).
Dyspnea and fever were present in all patients of both
groups, chest pain was present in 17 patients (85%) in group
1 and in 18 patients (90%) of group 2, productive cough was
present in 15 patients (75%) of group 1 and in 18 patients
(90%) of group 2 and hemoptysis was present in only one
patient (5%) in each group (see Table 2).
Leukocytic count was more in group 1 (14,370 ± 2830)
than group 2 (13,550 ± 2780) and ESR was also higher in
group 1 (60 ± 34) than group 2 (51 ± 29). The diameter of
induration was less than 5 mm in both groups (see Table 3).
In group one 2 patients (10%) had yellowish ﬂuid, 10
patients (50%) had turbid ﬂuid and 8 patients (40%) had frank
pus, in group two 2 patients (10%) had yellowish ﬂuid, 9
patients (45%) had turbid ﬂuid and 9 patients (45%) had frank
pus.
Direct Gram’s staining of group 1 patient samples showed
no organisms and three of group 2 patient samples
(15%)showed Streptococcus pneumoniae. Culture of the pleural
892 A. Hewidy, M. Elshafeyﬂuid was positive in 2 patients (10%) of group 1, one patient
had S. pneumoniae and one patient had Staphylococcus aureus
and in group 2, 3 patients (15%) had S. pneumoniae. ZN stain
for all patients was negative.
The mean value for pleural ﬂuid pH was 6.88 ± 0.25 in
group 1 and 6.97 ± 0.17 in group 2. The mean value for pleu-
ral ﬂuid protein was 4.14 ± 1.11 in group 1 and 4.05 ± 1.06 in
group 2. The mean value for pleural ﬂuid LDH was
491.60 ± 166.11 in group 1 and 457.85 ± 162.30 in group 2
and the mean value for pleural ﬂuid glucose was
42.25 ± 19.01 in group 1 and 37.00 ± 18.58 in group 2 (see
Table 4).
In group 1, 11 patients (55%) had right sided pleural effu-
sion while 9 patients (45%) had left sided pleural effusion. In
group 2, 8 patients (40%) had right sided pleural effusion while
12 patients (60%) had left sided pleural effusion.
In group 1, 7 patients (35%) had total improvement and
13 patients (65%) had partial improvement, in group 2, 2
patients (10%) had no improvement, 1 patient (5%) had
total improvement and 17 patients (85%) had partial
improvement.
In group 1, 19 patients (95%) had total improvement and 1
patient (5%) had partial improvement, in group 2, 7 patients
(35%) had total improvement and 13 patients (65%) had par-
tial improvement.
In group 1, 19 patients (95%) had total improvement and 1
patient (5%) had partial improvement, in group 2, 14 patients
(70%) had total improvement and 6 patients (30%) had partial
improvement but in CT chest conﬁrmed group 1 but in groupImage 1 shows multiple loculi
Image 3 shows cutting of adhesions by 
forceps
I
o2, 12 patients (60%) had total improvement and 6 patients
(40%) had partial improvement (see Table 5).
There was a signiﬁcant difference between both groups. In
group 1 only 1 patient persist to drain about 100 ml and was
referred to cardiothoracic surgery (see Table 6).
In group 1 after the MT no patients were diagnosed with
dyspnea, hemoptysis or fever, 1 patient with persistent cough,
2 patients with persistent chest pain and no patients with frank
pus with a decrease in WBC count to 9.51 ± 1.28. In group 2
after ICT-SK no patients were diagnosed hemoptysis, 3 patient
with persistent cough, 3 patients with persistent chest pain, 1
patient with dyspnea, 1 patient with fever and 1 patient with
frank pus with a decrease in WBC count to 9.15 ± 1.34. There
was a signiﬁcant difference in each group but there was no dif-
ference in signiﬁcance between both groups (see Table 7).
In group 1, 19 patients (95%) had total improvement and 1
patient (5%) had partial improvement, in group 2, 12 patients
(60%) had total improvement and 6 patients (40%) had partial
improvement with a signiﬁcant difference (see Table 8).
The duration of hospital stay was 4.70 ± 1.45 days in
group 1 and 6.95 ± 2.04 days in group 2 (see Table 9).
In group 1 only 3 patients had complications following
medical thoracoscopy, one patient had SC emphysema and
two patients had mild controlled bleeding and no mortality.
In group 2 only 5 patients had complications, one patient
had persistent empyema, one patient had mild bleeding, one
patient had SC emphysema and two patients had developed
mild allergic reaction injections and with no mortality (see
Table 10).Image 2 shows multiple adhesions
mage 4 shows pleural space become 
ne pouch at the end of the procedure
Table 3 Leukocytic count and ESR of both groups.
Group 1 Group 2 t P
MT (n= 20) ICT-SK (n= 20)
WBC 14.37 ± 2.83 13.55 ± 2.78 0.923 0.362
ESR 60.85 ± 34.99 51.95 ± 29.38 0.871 0.389
Tuberculin test 2.75 ± 3.89 4.25 ± 5.07 1.050 0.300
Table 4 Gross picture, bacteriology and biochemical analysis
of pleural effusion.
Group 1 Group 2 v2 P
MT (n= 20) ICT-SK (n= 20)
No % No %
Gross
Yellow 2 10 2 10 0.111 0.946
Turbid 10 50 9 45
Pus 8 40 9 45
Gram stain 0 0 3 15 3.243 0.072
Culture 2 10 3 15 0.229 0.633
ZN 0 0 0 0
pH 6.88 ± 0.25 6.97 ± 0.17 1.265 0.215
Protein 4.14 ± 1.11 4.05 ± 1.06 0.278 0.783
LDH 491.60 ± 166.11 457.85 ± 162.30 0.650 0.520
Glucose 42.25 ± 19.01 37.00 ± 18.58 0.883 0.383
Table 5 Radiological examination of both groups.
Group 1 Group 2 v2 P
MT (n= 20) ICT-SK (n= 20)
No % No %
CXR pre
Right 11 55 8 40 0.902 0.342
Left 9 45 12 60
CXR 1 day
No 0 0 2 10 7.033 0.030*
Total 7 35 1 5
Partial 13 65 17 85
CXR 5 days
Total 19 95 7 35 15.824 <0.001*
Partial 1 5 13 65
CXR discharge
Total 19 95 14 70 4.329 0.037*
Partial 1 5 6 30
Table 6 The average daily ﬂuid drainage in both groups.
Group 1 Group 2 t P
MT (n= 20) ICT-SK (n= 20)
pl_1 day 3500 ± 1142.02 1975 ± 727.56 5.037 0.000
pl_2 day 340.00 ± 180.35 1097.5 ± 507.44 6.290 0.000
pl_3 day 215.00 ± 112.51 527.50 ± 278.38 4.655 0.000
pl_4 day 126.92 ± 56.33 326.32 ± 184.37 4.422 0.000
pl_5 day 61.54 ± 41.60 192.11 ± 129.38 4.100 0.000
pl_6 day 100.00 125.00 ± 58.39 0.411 0.689
pl_7 day 100.00 87.50 ± 43.30 0.277 0.787
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Parapneumonic effusions and empyemas present difﬁcult
diagnostic and therapeutic challenges because of their highly
variable clinical presentation and response to therapy. It is esti-
mated that at least 40% of hospitalized patients with pneumo-
nia develop a parapneumonic effusion, which is associated
with an increased morbidity and a mortality of 15%. There
is a considerable variation in the clinical course of patients
with parapneumonic effusions [8].
The formation of a mature PE can be divided into three
stages: (i) the exudative stage, (ii) the ﬁbropurulent stage and
(iii) the organization stage. The exudative phase is character-
ized by a sterile exudate secondary to increased permeability
of the visceral pleura. The ﬁbropurulent phase represents pleu-
ral infection with the deposition of ﬁbrin on visceral and pari-
etal pleural membranes and the formation of loculations.
Pleural ﬂuid glucose and pH decrease and LDH increases in
pleural ﬂuid. The organization stage occurs with the inﬂux of
ﬁbroblasts into the pleural space and formation of inelastic
pleural peels and dense ﬁbrous septations. The rapidity and
extent of progression to a mature PE depend on the type
and virulence of the pathogen, the patient’s host defenses,
and the timing and effectiveness of antibiotic therapy. Various
classiﬁcations have been proposed to clinically stage the extent
of pleural inﬂammation and PPE formation [9].
The increased viscosity of pleural pus in patients with PE is
attributable to high concentrations of DNA resulting from the
breakdown of phagocytes, bacteria, and other intrapleural
cells. Streptodornase is a mixture of four DNAase enzymes
released by streptococci that reduces the viscosity of pus
through the digestion of DNA. In combination with ﬁbrino-
lytic drugs or used as a single agent, streptodornase liqueﬁes
pleural pus in vitro from patients and animal models with
PE more effectively than urokinase or streptokinase alone.
Clinical trials are needed to evaluate the efﬁcacy of streptodor-
nase in combination with ﬁbrinolytic drugs for patients with
highly viscous, multiloculated PE that fail chest tube drainage
[10].
Generally accepted indications for the use of thoracoscopy
in infected pleural space have yet to be agreed [11,12]. Some
authors maintain that it should be used before positioning a
chest tube, when chest tube insertion is indicated [13]. Others
consider that it should be used only when a large-caliber chest
drain does not bring about reduction of fever and complete
radiological resolution of the effusion after 2–3 days [14,15].
Medical thoracoscopy, as a drainage procedure intermedi-
ate between tube thoracostomy and VATS, is signiﬁcantly
lower in cost and can avoid surgical thoracoscopy under gen-
eral anesthesia. It is essential that it is performed early in the
course of empyema and it is particularly advisable for frail
patients at high surgical risk [13].
Cases on the use of thoracoscopy in pleural space infections
are mainly related to empyema and are principally surgical.
They generally describe favorable results, with primary success
rates (complete recovery without the need for subsequent
thoracotomy or conversion of VATS to thoracotomy) of 60–
100%. In the present authors’ experience of medical thoracos-
copy, in 69 cases, the primary success rate was 93% and only
ﬁve patients needed a surgical intervention by VATS or thora-
cotomy (unpublished data). The best results were obtained
Table 7 The clinical and laboratory endpoints in both groups.
Group 1 P Group 2 P
MT ICT-SK
No. before No. after No. before No. after
Dyspnea 20 0 <0.001 20 1 <0.001
Productive cough 15 1 <0.001 16 3 <0.001
Chest pain 17 2 <0.001 18 3 <0.001
Hemoptysis 1 0 0.317 1 0 0.317
Fever 20 0 <0.001 20 1 <0.001
Frank pus 8 0 0.005 9 1 0.005
WBC 14.37 ± 2.83 9.51 ± 1.28 <0.001 13.55 ± 2.78 9.15 ± 1.34 <0.001
Table 8 The radiological endpoints (CT chest) in both
groups.
Group 1 Group 2 v2 P
MT (n= 20) ICT-SK (n= 20)
No % No %
CT discharge
Total 19 95 12 60 7.025 0.008*
Partial 1 5 8 40
Table 9 The hospital stay in both groups.
Group 1 Group 2 t P
MT (n= 20) ICT-SK (n= 20)
Duration of stay 4.70 ± 1.45 6.95 ± 2.04 4.018 0.000
Table 10 Complications in both groups.
Group 1 Group 2 v2 P
MT (n= 20) ICT-SK (n= 20)
No % No %
Persistent empyema 0 0 1 5 1.026 0.311
Mild bleeding 2 10 1 5 0.360 0.548
Severe bleeding 0 0 0 0 – –
SC emphysema 1 5 1 5 0 1.0
Allergy 0 0 2 10 2.105 0.147
Mortality 0 0 0 0 0 1.0
894 A. Hewidy, M. Elshafeywhen the method was applied early in the course of the disease
[16].
Medical thoracoscopy has played a marginal role in the
treatment of empyema for a long time, but has become more
and more established in recent years. It can be performed in
analgo-sedation in a bronchoscopy suite. It is minimally inva-
sive and costs are much lower compared to surgical VATS.
The diagnostic and therapeutic power seems to be comparable
to VATS, since several studies show success rates with medical
thoracoscopy between 73% and 100% [17].
Intrapleural ﬁbrinolytic therapy agents offer a promising
alternative and have been reported as an effective adjunct to
accelerate drainage of loculated effusions in complicatedempyema [18] Fibrinolytic agents are believed to work through
decreasing ﬁbrinous strands and reopening pleural pores
blocked by ﬁbrinous material, permitting pleural resorption.
Streptokinase was ﬁrst used by Tillett in 1949 to lyse ﬁbrinous
pleural material and break down loculi. [19].
Intrapleural ﬁbrinolytic therapy was ﬁrst used in 1949 by
Tillet and Sherry, who used partially puriﬁed streptococcal
ﬁbrinolysin that contained both streptokinase and streptodor-
nase (a DNAse) to drain infected postoperative hemothoraces
[20].
More recently, observational series and small randomized
trials showed that these agents improved pleural ﬂuid drain-
age, and it was therefore widely assumed they would improve
long-term patient outcome. However, a recent large random-
ized trial showed that these short-term drainage beneﬁts are
not associated with reduced mortality, the frequency of sur-
gery, the length of hospital stay or long-term radiological
and lung function outcome [6].
Intrapleural ﬁbrinolytic therapy remains an option for poor
surgical candidates who fail chest tube drainage or who require
a period of medical stabilization before surgery is performed.
Fibrinolytic drugs are most likely to be successful in patients
with early PPE. Additional investigations are needed to con-
ﬁrm these recommendations and to evaluate the role of anti-
ﬁbrotic, DNAase, and other ﬁbrinolytic drugs both as primary
and adjunctive therapy [21].
Against this background, the MIST1 trial reported its ﬁnd-
ings in 2005. The study recruited 454 patients across 52 UK
hospitals, and was powered to address whether streptokinase
altered combined death and surgical rate. There was no differ-
ence between SK and placebo groups in death or surgery ana-
lyzed separately, length of hospital stay, radiographic change
or lung function at 3 months. Subgroup analyses demonstrated
no difference between streptokinase and placebo regardless of
characteristic studied (pleural ﬂuid purulence, complicated
parapneumonic effusion, short clinical history, initial amount
of radiographic effusion) [22].
Thus, current evidence does not support the routine use of
intrapleural ﬁbrinolytic agents. On occasions, such treatment
may be indicated for the physical decompression of multilocu-
lated (and so tube drainage resistant) pleural ﬂuid collections
that are responsible for dyspnea or respiratory failure if discus-
sion with a thoracic surgeon identiﬁes that either surgery is not
immediately possible due to additional patient co-morbidity,
the feasibility of transfer to a surgical unit or other clinical
or logistical reasons [6].
Medical thoracoscopy versus intrapleural ﬁbrinolytic therapy 895As we do not have VATS in our hospital we tried to
show the efﬁcacy of MT in the management of complicated
parapneumonic effusion and empyema comparing it to
commonly used therapies tube thoracostomy with streptoki-
nase as initial treatments. We found that MT is uniformly
successful, well tolerated, and associated with better
outcome.
In our study success rate of intrapleural streptokinase was
60% in group 2 less than Bergh et al. (100%) [23], Bouros
et al. (95%) [24] and Roupie et al. (88%) [25] as they studied
less number of patients (12, 15 and 16, respectively) and com-
pared it to placebo injection in the intercostal tube, our success
rate was more than Fraedrich et al. (44%) [26] as they studied
larger number of patients (27 patients) with more patient
needed decortication (15 patients) and our success rate was
near to Laisaar et al. (68%) [27] and Temes et al. (69%) [28]
as they studied similar number of patients (21 and 19 patients
respectively).
In some series SK treatment is reported to have no beneﬁ-
cial effect on hospital stay, given a mean of 3 weeks [29]. In our
study, however, mean hospital stay was signiﬁcantly shorter
for Group 2 patients about 1 week as we started injection
earlier.
Our results in group 1 were comparable to Wait et al. [7]
study who compared streptokinase injection to VATS their
success rate in VATS (91%) was similar to ours (95%) and
they studied less number of patients (11 patients).
We have no any serious complications where in group 1
only 3 patients had complications following medical thoracos-
copy, one patient had SC emphysema and two patients had
mild controlled bleeding and no mortality. In group 2 only 5
patients had complications, one patient had persistent empy-
ema, one patient had mild bleeding, one patient had SC
emphysema and two patients had developed mild allergic reac-
tion and with no mortality. These results are comparable to
Wait et al. [7] study in which only two patients developed mild
allergic reaction at the 4th and 5th injection and two patients
complained of back pain.
Conclusion
Medical thoracoscopy is superior to streptokinase ﬁbrinolysis
in complicated parapneumonic effusions and empyema in
terms of safety and efﬁcacy.
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